Considering that HDAC class I and IIb enzymes are elevated and critical for CML cell survival, we next evaluated the in vitro inhibitory potency of martinostat and its drug-likeness properties to determine its suitability as a pan-HDAC inhibitor for CML treatment. The gene discussed is HDAC9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.